HMLSF yields 1.41% · JNJ yields 2.13%● Live data
📍 JNJ pulled ahead of the other in Year 7
Combined, HMLSF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of HMLSF + JNJ for your $10,000?
HMMJ seeks to closely replicate the performance of the North American Marijuana Index. This index is specifically crafted to offer exposure to a diversified basket of North American publicly listed companies heavily involved in the marijuana industry. Unlike investing in a single marijuana company, HMMJ offers diversified exposure to a basket of North American publicly listed companies within the industry, reducing the risk associated with individual securities while still capturing the potential upside of the sector. With the marijuana industry rapidly evolving, HMMJ is rebalanced quarterly to ensure the portfolio reflects the changing landscape, providing investors with exposure to the industry's shifting leadership and growth drivers. HMMJ seeks to replicate, to the extent possible, the performance of the North American Marijuana Index, net of expenses. The North American Marijuana Index is designed to provide exposure to the performance of a basket of North American publicly listed companies with significant business activities in the marijuana industry
Full HMLSF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.